Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04449484 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT04449484 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 25 participants.
The verdict
NCT04449484, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled study of multiple ascending iv doses of MEDI341 in male and female subjects with Parkinson's Disease.
Interventions
- OTHER Placebo
- DRUG MEDI1341
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2022-01-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04449484
The ClinicalTrials.gov registry entry for NCT04449484 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04449484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04449484 about?
NCT04449484 is a clinical study titled "Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease". This is a multicenter, randomized, double-blind, placebo-controlled study of multiple ascending iv doses of MEDI341 in male and female subjects with Parkinson's Disease.
What is the current status of trial NCT04449484?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2020-08-04. Estimated completion is 2022-01-05.
What interventions are being tested in trial NCT04449484?
The interventions under investigation include: Placebo (OTHER), MEDI1341 (DRUG).
Who is sponsoring clinical trial NCT04449484?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.